Method of treating patients with bronchial asthma with accompanying hypertension

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to therapy, physiotherapy, balneology. Method includes carrying out respiratory gymnastics, inhalations with mineral water, manual massage of chest, applications of peloids, electric stimulation at the background of drug basic therapy. During electric stimulation impact is performed by high-amplitude pulse current with biological feedback, with frequency 90-100 Hz and gradually increasing current intensity until sensation of painless vibration appears. On the first day impact is performed paravertebrally at the level D1-D7 and along 7-8 intercostal spaces. On the second day impact is performed paravertebrally and on collar area. Peloid therapy is carried out 20-30 minutes after electric stimulation. In first application impact is performed on chest at temperature 38-40°C and 20-30 minute exposure. On the second day of application impact is performed on collar area at temperature 35-36°C. Course of treatment includes 6-7 coupled impacts on each zone.

EFFECT: method increases treatment efficiency and increases remission duration due to expressed local and systemic anti-inflammatory effect.

2 tbl, 2 ex

 

The invention relates to medicine, namely to physiotherapy and balneology, and can be used for the treatment of patients with bronchial asthma, having as comorbidity hypertension.

Comorbidity of bronchial asthma (BA) and hypertensive disease (HD) is a common worldwide, accounting according to various researchers from 7 to 53% of the total number of patients with BA [1, 2].

It is known that these two pathologies not only have common mechanisms of pathogenesis (impaired antioxidant defense, and others), but are vzaimootnoshenii, accelerating the progression of both diseases and impairing their quality treatment. In particular, among other reasons, the failure to achieve control of asthma indicates the presence of comorbidities [3].

The presence of comorbidity, doctors increase the drug load on the patient, which is not always desirable, since the probability of allergic reactions and complications.

There is a method of treating bronchial asthma patients with concomitant hypertension physical factors [4], providing for the appointment of inhalations, massage, exercise therapy, mud therapy and currents supersonic frequency. The disadvantage of this method is: a) not enough pronounced local anti-inflammatory effect (impact on m is local inflammation in the respiratory tract); b) the lack of positive corrective influence on the state of lipid metabolism.

There is a method of treatment of hypertension SCENAR-therapy and iodobromide baths [5]. As a result of its use in patients with essential hypertension improves clinical symptoms, decreases blood pressure, improves circadian rhythm of blood pressure, diastolic function of the heart, etc. But the method is not designed and has not been studied relative to the treatment of patients with BA.

Closest to the claimed is a method of treatment of hypertension in combination with bronchial asthma [6], including medication basic therapy, breathing exercises, inhalation of mineral water, manual massage of the chest, application of peloids, iodobromide baths and SCENAR-therapy of reflex zones and the area of projection of the light.

The disadvantage of this method is the lack of impact on the local inflammatory process in the respiratory tract, i.e. one of the main pathogenetic links of bronchial asthma.

New technical problem is the rise of effektivnosti way due to the more pronounced local and systemic anti-inflammatory action that helps to decrease subsequent exacerbations.

To solve the problem in the treatment of patients with bronchial asthma is associated hypertension, including on the medical background of basic therapy of respiratory gymnastics, inhalation of mineral water, manual massage of the chest, applications of peloids, electrical stimulation of reflex zones and the area of the projection light, the procedure pelotherapy spend 20-30 minutes after electrical stimulation in the first half of the day, for the stimulation effect of high-amplitude pulse of current with a biologically feedback, frequency 90-100 Hz and gradually increasing current strength until you feel painless vibration, labile technique for 20 minutes: one day paravertebral level 1-d and during 7-8 intercostal space, the second day - and paravertebral on the collar area, and applications peloid spend the first day on the chest at a temperature of 38-40°C and exposure 20-30 minutes, the second - on collar region at a temperature of 35-36°C, only for the course of treatment prescribed by 6-7 dual effects on each area.

The method is as follows. The treatment is carried out by assigning a single building on the background of physical therapy, massage and inhalation, applications peloid and SCENAR-therapy. The effect of high-amplitude pulsed bipolar current with biologically feedback exercise on labile methodology in the morning with a frequency of 90 to 100 Hz with a gradual increase of strength t is ka to feel painless vibration, the total duration of the procedure 20-25 minutes. Act one day at paravertebral area level 1 - d and region 7-8 intercostal space from the paravertebral to axillary line. The second day affect paravertebral and collar zone, moving the electrode from the paravertebral line to the shoulder joint.

After 20-30 minutes are peloidoterapiya with effect on the same two fields: one day applications impose on the back (the back surface of the chest) at T 38-40°C and exposure 20-30 minutes, the other on the collar area with a temperature of 35-36°C. at the rate of 6-7 dual effects on each field. Comprehensive treatment of physical factors perform on the background of basic medical therapy for both diseases.

Use in the claimed method of application of peloids due to their pronounced anti-inflammatory effect, a positive effect on immune status and lipid metabolism [7, 8]. The choice of the temperature regime is based on data proving the existence of therapeutic effect as in the pathology of the respiratory organs, and hypertension [7, 8].

Inclusion in the medical complex self controlled Energo neuro adaptive electrical stimulation (SCENAR-therapy) due to its ability to regulate metabolism (lipid, carbohydrate), the increase in the hypotensive E. the reaction, improving Central and intracardiac hemodynamics [9]. Frequency 90-100 Hz selected based on the availability of anti-inflammatory and bronchodilatory actions [10].

The time of the procedure in the morning due to the fact that in this period of the day to the greatest degree stimulates metabolic processes, including also corrected lipid, increase adaptive capacity, enhancing the function of homeostatic systems. [11].

The duration of treatment in the form of 6 dual impacts on every area due to the fact that, according to most researchers, therapeutic effect when assigning physical factors begins to manifest after 5 treatments. A longer course may cause the patient " fatigue treatment" and the failure of adaptive mechanisms.

Clinical examples

Example 1

Patient WAV, 26 years old, medical history, No. 936, the duration of treatment 11.04.07-28.04.07.

Diagnosis: Bronchial asthma, exogenous, moderate severity. Hypertension 2 tbsp., risk 3. Allergic rhinitis. Upon receipt complained of asthma up to 2 times per day, including 1-2 attack at night, shortness of breath in the interictal period, cough, shortness of breath, headaches, dizziness, feeling of "stuffiness" of the nose. As a basic therapy gets beclazone (250 µg) 2 on the PS 2 times a day, if necessary, up to 2 inhalations beroteka. Antihypertensive therapy in the form of receiving Diroton 5 mg/day. When this blood pressure at the time of admission 140/85 mm Hg

Blood biochemical parameters before treatment: total cholesterol 7,34 mmol/l (normal up to 5.17 mmol/l), cholesterol-low-density lipoprotein a 4.86 mmol/l (normal up to 3.0 mmol/l), atherogenic index was 4.02 USD (at a rate of up to 3.0 cu), catalase 39,9 has metal/l (normal 16-30 has metal/l)ceruloplasmin 390 mg/l (at a rate of up to 400 mg/l), malonic of dialdehyde 4.4 mmol/l (normal up to 3.6 mmol/l) myocardial Contractility normal: PV according to Echocardiography 77% (at a rate of between 60% and above), CSR 30 ml (at a rate of up to 54 ml), BWW 134 ml (normal up to 150 ml), the ratio of the velocity of early filling of the left ventricle to the velocity of late filling of the left ventricle E/1,58 $ (at a rate above $ 1,0), time isovolumic relaxation of the myocardium 65 MS (at a rate of up to 95 MS) - impaired diastolic function of the left ventricle is not revealed. Indicators spirography no signs of ventilation failure. From the immunological status of the marked signs of active inflammation according to the spontaneous NBT-test - 34% (at a rate of up to 15%), IgA to 4.2 g/l (at a rate of up to 3.0 g/l), and the activity of lysozyme - 34% (at a rate of up to 30%). According to the General analysis of blood marked the high level of eosinophils to 8% (but the IU do%). For assessment of the degree of tension nonspecific adaptive mechanisms defined the type of adaptation reactions and the level of reactivity Phharmacy et al. - identified reaction peaceful activation low level of reactivity.

Analysis of state and local protection factors for respiratory tract according to nasal secretion and content in the exhaled air of nitric oxide testified to the activity of the inflammatory process: the level of sialic acid - strength of 0.159 g/l (at a rate of up 0,122 mmol/l), lysozyme - 67% (at a rate of up to 53%), protein of 0.95 mg/ml, nitric oxide - 2,732 mmol/l (normal up to 0.8 mmol/l).

The treatment was carried out in accordance with the claimed method. On the background of basic medication therapy patient were appointed: inhalation of saline daily, respiratory gymnastics daily massage of the chest through the day. SCENAR-therapy was administered in the morning, high amplitude pulsed bipolar current with biologically feedback (with automatic shut-off at the equation level of impedance inside the device and in the skin), was affected by the frequency 90-100 Hz, when the duration of the procedure 20 minutes. The exposure was carried out one day on the paravertebral area level 1-d and region 7-8 intercostal space, the second day of paravertebral and collar zone, with a gradual increase in the strength of the current is until a clear painless vibration under the electrode, on labile technique daily. Applications peloid was performed 20 minutes after SCENAR-therapy: one day on the collar area with a temperature of 36°C and exposure 30 minutes, the second day - on the rear surface of the chest, at a temperature of +40°C; exposure to 30 minutes, in the course of 7 treatments per area.

Treatment the patient endured well. Clinical manifestations of baldereschi were not recorded. Sharp fluctuations in autonomic indices characterizing autonomic tone and reactivity, not identified. After treatment by the present method, the patient disappeared nocturnal attacks of breathlessness, headaches, false angina, palpitations. Blood pressure after treatment decreased from 140/85 to 120/65 mm Hg While there was an improvement in the lipid spectrum of blood: the concentration of total cholesterol was down to 5.68 mmol/l, cholesterol-low density lipoprotein to 1.48 mmol/l, the atherogenic index to 2.48$, normalized levels of catalase (after treatment - 27,9 has metal/l). The characteristics of systemic immunity happened dynamics, indicating a decrease in the severity of inflammation: the values of spontaneous NBT-test decreased from 34%to 20%, increased biocenose neutrophils from 1.15 up to 2.15%, decreased blood levels of IgA (from 4.2 to 2.6 g/l), lysozyme (from 34%to 30%). According to the General analysis of blood marked the norms of the implementation level of eosinophils to 1%. The treatment had a positive effect on the adaptation capabilities of the patient has changed the level of reactivity from low to high. Dose hypotensive and bronchodilatory drugs decreased: Diroton to 2.5 mg/day, broncholytic short-term action (Berotec) cancelled. The decreased activity of the local inflammatory process was confirmed by positive dynamics of the content of sialic acids in natalem secret (strength of 0.159 to 0,096 mmol/l), lysozyme up to 64%, nitrogen oxide to 0.35 mmol/l On a set of clinical and paraclinical data the effectiveness of the treatment were assessed as an improvement.

Example 2

Patient CNM, 58 years old, medical history, No. 67, duration of treatment 10.01.08-29.01.08.

Diagnosis: Bronchial asthma endogenous, moderate severity. Hypertension 1 tbsp., risk 2. Chronic allergic rhinitis. At admission the patient disturbed daytime attacks of breathlessness (2-3 times a day), nocturnal attacks of breathlessness (1-2), shortness of breath on mild exertion, cough, Department of mucous sputum, headache, fatigue, weakness, insomnia. The patient received basic asthma therapy in the form of no seretid (250/50 mcg 2 times a day). Against this background, 4-5 times a day used berodual. On spirographic data breach ventilation was not. Antihypertensive therapy: amlodipine 5 mg/day. Upon receipt of the ar is realnoe pressure 150/90 mm Hg

Blood biochemical parameters before treatment: total cholesterol ratio - 5.24 mmol/l (normal up to 5.17 mmol/l), HSLP EAP is 0.99 mmol/l (normal is above 1.2 mmol/l), atherogenic index - 4,29 $ (at a rate of up to 3.0 cu), catalase - 35,9 has metal/l (normal 16-30 has metal/l)ceruloplasmin - 410 mg/l (at a rate of up to 400 mg/l), malonic dialdehyde - 3.4 mmol/l (normal up to 3.6 mmol/l)the fibrinogen - 4.4 g/l, sialic acid - to 2.65 mmol/l (normal up to 2.5 mmol/l). Myocardial contractility is normal: PV according to Echocardiography - 66% (at a rate of between 60% and above), CSR - 47 ml (at a rate of up to 54 ml), MLC - 140 ml (normal up to 150 ml). The ratio of the velocity of early filling of the left ventricle to the velocity of late filling of left ventricular E/A - 0,83 $ (at a rate above $ 1,0), time isovolumic myocardium relaxation - 100 MS (at a rate of up to 95 MS) is an infringement of diastolic function of the left ventricle. Right ventricle at the upper limit of normal, slightly expanded the left atrium.

Analysis of state and local protection factors for respiratory tract according to nasal secretion and content in the exhaled air of nitric oxide testified to the activity of the inflammatory process: the level of sialic acid - 0,374 mmol/l (normal up, 0,122 mmol/l), lysozyme - 58% (at a rate of up to 56%), protein - nasal secret of 2.33 mg/ml (at a rate of up to 0.72 mg/ml).

The treatment of the patient carrying the force of good. SCENAR-therapy was administered in the morning, high amplitude pulsed bipolar current with biologically feedback and frequency 90-100 Hz, with a treatment duration of 25 minutes. Impact spent one day on the paravertebral area level 1-d and region 7-8 intercostal space from the paravertebral to axillary line, the second day of paravertebral and collar zone, and gradually increase the current until a clear painless vibration under the electrode, labile technique daily. Applications peloid was administered after 30 minutes on two fields, alternating days: one day at collar region at a temperature of +35°C, exposure to 20 minutes, the second day - on the rear surface of the chest, at a temperature of +38°C; exposure to 20 minutes, at the rate of 6 dual procedures for each area.

After treatment was complete relief of daytime and nighttime asthma attacks, spirographis indicators during treatment has not changed, remaining within the normal range. Blood pressure after treatment decreased from 150/90 to 120/80 mm Hg Improved ratio of early and late filling of the left ventricle from 0.83 to 1.01 $ (the norm than 1.0 USD). Marked improvement in contractility (decreased CSR to 38 ml of BWW to 130 ml). Time isovolumic rasla the population decreased to 80 MS. Normalized source of altered biochemical parameters of blood: ceruloplasmin - 345 mg/l of malonic dialdehyde - 2.1 mmol/l, catalase - 22,0 has metal/l, fibrinogen - 3.0 g/l, sialic acid - 2,3 mmol/l decrease in haemoglobin to 3,57 $ From the indices of systemic immunity on reducing the severity of inflammation testified: the decrease in the values of spontaneous NBT-test from 31 to 21%growth in biocenose neutrophils from 1.0 to 3.2, the normalization of the content of IgM from 0.74 to 2.2 g/l, JgG from 17.5 15.4 g/L.

Local anti-inflammatory effect was documented by lower contents in natalem secret of sialic acids with 0,374 to 0,253 mmol/l of lysozyme from 58 to 37%, total protein from 2.33 to 0.68 mg/ml

Dose of drugs after treatment by the present method decreased berodual from 4-5 to 1-2 times per day. The immediate results of the treatment were assessed as a significant improvement (increase of the integral index of health from 42.0 to 60.0%).

A new method of complex treatment of patients with BA with concomitant hypertension, if this optimization pelotherapy is achieved by the fact that it is carried out in 20-30 minutes after exposure to the procedures of SCENAR-therapy on the same zone with respect to certain temperature and taking into account daily biorhythms.

Treatment is claimed method received 26 patients with bronchial asthma, average age amounted to 49.3±10.5 years, and the average disease duration of 10.3±7.8 years. In 55.6% of observations were women. Endogenous asthma was in 73% of patients, exogenous at 27%. Mild asthma had 8 (30,8%) patients, moderate in 15 (57.6 per cent), heavy - 3 (11.6 percent). On the average, the frequency of exacerbations of the disease for the year was 2.3±1.1 times per surveyed. All patients received basic drug therapy in accordance with the requirements of GINA, 2006 [12].

Hypertension stage 1 was as comorbid disease in 14 (53.8%) of patients, 2nd - 12 (46,2%).

Criteria of efficiency of treatment: reduce the frequency and severity of nocturnal and daytime attacks of breathlessness, the severity of the cough, needs broncholytic short steps, higher values of FEV1 (according to spirography), reducing the severity of local inflammation (according to a study of nasal swabs and content of nitric oxide in exhaled air). About systemic anti-inflammatory and immunomodulating effect of the treatment is testified dynamics of clinical, biochemical and immunological parameters of blood. The effectiveness of treatment relative to GB, in addition to the reduction in office BP, testified: the condition of lipid and carbohydrate metabolism, data circadian blood pressure profile, Central and intracardiac hemodynamics.

As a group relative to the s to the claimed method are analyzed treatment results for the prototype (SCENAR and iodide-bromine baths) - 24 BA patients with concomitant GB. Both groups were matched for severity of underlying and related diseases.

The treatment prescribed by the present method, is well tolerated and contributed to a significant reduction of clinical manifestations BA: as a result of treatment were cropped nocturnal attacks of breathlessness (prior to treatment were observed in 42.3% of patients), by 53.9% less likely to become lodged complaints of daytime attacks of breathlessness, by 53.8% to cough. The need for broncholytic short steps decreased 3 times. Regarding complaints related to GB, there has been a decrease of complaints about false angina (39%), headache (48%). All patients had normal sleep.

Treatment by the present method, as well as the treatment of prototype, contributed to the decrease in office systolic and diastolic blood pressure, improve the daily profile of blood pressure, contractile myocardial function, diastolic function of the heart. Thus, characterizing the dynamics from the side of the circadian blood pressure profile in the group of patients treated by the present method, it is revealed that after treatment increased systolic pressure during the day were recorded 54.5% less (9,1 against 63,6% before treatment; P<0.01), and diastolic by 36.3% less (9,1 against 45,4%, P<0,02), increased systolic blood pressure at night by 36.3% less (27,3 against 63,6%; P<0.01), and the time index SA the day - 26.5% (9,9 against 63,6%; P<0.01), and the time index DBP day - by 26.5% (9,9 against 36,4%; P 0.05), and the variability of DBP night - 26.5% (9,9 against 36,4%; P<0,05).

By echocardiography was observed beneficial effect of treatment on diastolic function of the heart, which was manifested by the increase of the ratio E/A (before treatment - 0,89 [0,81; 1,19], after - 1,03 [0,88; 1,24]; P<0.03), and lower VIR (80,0 [75,0; 82,5] to 75,0 [66,2; 80,0]; P<0,007).

The inventive method and the prototype was improved lipid profile, reduction of glucose level.

The difference between the compared treatments lies in the effect on inflammation in the respiratory tract (table 1). If the claimed method of the anti-inflammatory effect testified dynamics of all the considered parameters (decreased high content of sialic acid, protein, lysozyme in nasal swabs, nitric oxide in exhaled air), the prototype of this effect is not identified. The inventive method had anti-inflammatory effect on the system level (table 2), as evidenced by the decrease in blood sialic acid, ceruloplasmin, catalase and eosinophils. In the comparison group such dynamics were absent. Anti-inflammatory effect of treatment by the present method was confirmed by immunological data in the form of lower content in the blood increase the military value NBT-test (spontaneous) 58,0 [40,5; 69,7] to 43,0 [21,3; 52,2]%; p=0.03; IgA with 3.5 [2,5; 4,12] 2.4 [1,8; 4,1] g/l; p=0.02; lysozyme from 35.0 [33,5; 36,5] to 32.0 [27,0; 34,3]%; p=0.04), higher index biocenose neutrophils from 1.24 [0,9; 1,39] to 1.45 [1,25; 2,4]; p=0.05. In the comparison group on any of these indicators of positive dynamics after treatment were not identified.

Treatment as claimed method and the comparison group improved bronchial obstruction according to spirography. The difference between groups was that the treatment by the present method resulted in relief of sudden interruption of ventilation (to ensure they were 15% of patients). In the comparison group there was an increase (24.6%, P<0,05) number of patients without disorders of ventilation due to patients having to treat minor violations.

In General, after treatment by the present method of 69.2% of patients had no violations by bronchial obstruction, and 84.6% of them had achieved control of asthma, 84,7% had completed treatment with a positive result, which was maintained at an average of 10.5±2.6 months, and the frequency of exacerbations over the next year observations were decreased 2.6 times. In the comparison group immediate effectiveness of treatment was equal to that of the claimed method (83,3%), but the persistence of the achieved therapeutic effect was shorter (7,3±0.8 months), and reduce the frequency of exacerbations is smaller (1.9 times)./p>

Thus, the application of the proposed method for the treatment of bronchial asthma patients with concomitant hypertension allows to achieve a significant improvement from the basic pathogenesis of BA - inflammation due to pronounced local and systemic anti-inflammatory action, which suggests a higher quality of treatment to achieve more significant ischemia subsequent exacerbations. This positive impact on the GB, retained as significant as in the prototype.

Table 1
Indicators of activity of local inflammation
IndicatorsThe inventive method (n=26)The comparison group(n=24)
PP
Sialic acid nasal secretions, >0,247 mm/l0,011
Protein nasal secretions, >0,91 g/l0,0110,073
Lysozyme nasal secretions, >59,9%0,006
NO breath >1.0 mmol/lbeing 0.036
Me - median; LQ, UQ - upper and lower quartiles; NO - nitric oxide

Table 2
The activity indicators of systemic inflammation (according to the data of biochemical parameters of blood)
IndicatorsThe inventive method (n=26)The comparison group (n=24)
P P
Sialic acid >2.5 mmol/l0,01
Ceruloplasmin, >400 mg/l0,001
Catalase, >30 were metal/l0,05
Eosinophils, >4%0,043

A method of treating bronchial asthma patients with concomitant hypertension, including on the medical background of basic therapy of respiratory gymnastics, inhalation of mineral water, manual massage of the chest, applications of peloids, stimulation of reflex zones and the area of projection of the lungs, characterized in that the procedure pelotherapy spend 20-30 mi is after electrical stimulation in the first half of the day, for the stimulation effect of high-amplitude pulse of current with a biologically feedback, frequency 90-100 Hz and gradually increasing current strength until you feel painless vibration, labile technique for 20 minutes: one day paravertebral level 1-d and during 7-8 intercostal space, the second day - and paravertebral on the collar area, and the application peloid spend the first day on the chest at a temperature of 38-40°C and exposure 20-30 minutes, the second - on collar region at a temperature of 35-36°C, only for the course of treatment prescribed by 6-7 dual effects on each area.



 

Same patents:

FIELD: chemistry.

SUBSTANCE: invention relates to novel substituted pyrimidine derivatives having PGDS inhibiting properties. In formula (I): (I), R1 denotes phenyl or a 5- or 6-member heteroaryl containing 1-3 heteroatoms selected from N, O and S, each optionally having one or more of the following independent substitutes: halogen, (C1-C6)-alkyl, or (C1-C4)-haloalkyl; R2 denotes hydrogen or (C1-C6)-alkyl, which is optionally substituted with one or more halogens; R3 denotes hydrogen, (C1-C6)-alkyl or phenyl; R4 denotes C6-cycloalkyl, phenyl, a 6-member heterocyclyl containing one N heteroatom, a 6-member heteroaryl containing one N heteroatom, -C(=O)-NY1Y2, -C(=S)-NY1Y2, or -C(=O)-R5, where the phenyl, 6-member heteroaryl or 6-member heterocyclyl group optionally has one or more independent substitutes R6, or R3 and R4 together with a nitrogen atom with which they are bonded form a 5- or 6-member heterocyclyl containing one or two heteroatoms selected from N, O and S, a 6-member heterocyclenyl containing two or three N heteroatoms, a 5-member monocyclic or 9-member bicyclic heteroaryl containing one to three N heteroatoms, phenylheterocyclyl, where the heterocyclyl is 5- or 6-membered and contains one or two heteroatoms selected from N and O, each optionally having one or more independent substitutes R6. Values of R5, R6, Y1, Y2 are given in the claim. The invention also relates to a pharmaceutical composition containing said compounds.

EFFECT: improved method.

15 cl, 227 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely pulmonology, and can be used for treatment of patients with chronic obstructive lung disease. For this purpose, complex therapy, which includes carrying out nebuliser inhalations of lysocium and gas-air carbon dioxide baths at the background of symptomatic drug therapy and respiration gymnastics, is realised to patient. In order to carry out nebuliser inhalations ofr lysocium, content of lysocium bottle - 0.05 g is preliminarily dissolved in 10 ml of isotonic sodium chloride solution. 4 ml of lysocim solution are poured into nebuliser chamber. Inhalations are performed for 7-9 minutes, daily, 10-12 procedures per course. Then, after 30-60 minutes gas-air carbon dioxide baths with temperature of gas mixture 36°C are carried out, exposure time is 20-25 minutes, daily, 12-15 procedures per course. Mixture supply is realised for 6-7 minutes at rate 50 l/min. carbon dioxide concentration constitutes 43-48%.

EFFECT: method ensures increase of treatment efficiency due to expressed anti-inflammatory and broncholytic action, improvement of humoral immunity and gas-exchange function of lungs with reduction of drug load on organism.

2 ex

FIELD: medicine.

SUBSTANCE: invention refers to a new compound of formula or to its pharmaceutically acceptable salt. What is prepared and described is the new compound applicable as a modulator of ATP-binding cartridge (ABC) transporter or their fragments including a cystic fibrosis transmembrane regulator (CFTR).

EFFECT: higher efficacy.

1 cl, 422 ex, 7 tbl

FIELD: medicine.

SUBSTANCE: invention refers to compounds of formula (I) and their pharmaceutically acceptable salts possessing the properties of a MMP12 inhibitor, a method for preparing them, an intermediate compound of formula (III), a pharmaceutical composition, a method for preparing it, using the compounds of formula (I) and versions of methods of treating with the use of the compounds of formula (I). The compounds may be used for treating the MMP12-mediated diseases, such as chronic obstructive pulmonary disease. In formula (I) and (III) R1 represents H, CH3, CH3CH2, CF3 or cyclopropyl; and R2 represents H or CH3.

EFFECT: higher clinical effectiveness.

15 cl, 1 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: invention refers to compounds of formula (I) and their pharmaceutically acceptable salts possessing the properties of a MMP12 inhibitor, a method for preparing them, an intermediate compound of formula (III), a pharmaceutical composition, a method for preparing it, using the compounds of formula (I) and versions of methods of treating with the use of the compounds of formula (I). The compounds may be used for treating the MMP12-mediated diseases, such as chronic obstructive pulmonary disease. In formula (I) and (III) R1 represents H, CH3, CH3CH2, CF3 or cyclopropyl; and R2 represents H or CH3.

EFFECT: higher clinical effectiveness.

15 cl, 1 tbl, 6 ex

FIELD: chemistry.

SUBSTANCE: invention relates to substituted sulphamide derivatives of formula I: , in which n, m, R1, R2a-c, R3, R4, R5 and R6 are as described in claim 1, in form of a racemate, enantiomers, diastereomers, mixtures of enantiomers or diastereomers or a separate enantiomer or diastereomer, bases and/or salts of physiologically compatible acids. The invention also relates to a method of producing said compounds, a medicinal agent having antagonist action on bradykinin receptor 1 (B1R), containing such compounds, use of such compounds to produce medicinal agents, as well as sulphamide-substituted derivatives selected from a group of compounds given in claim 8.

EFFECT: providing novel compounds which are suitable as pharmacologically active substances in medicinal agents for treating disorders or diseases which are at least partially transmitted through B1R receptors.

13 cl, 581 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of invention refers to medicine, and concerns treating nonsense mutation(s) associated diseases: Duchene muscular dystrophy and cystic fibrosis. What is presented is the use of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazole-3-yl]benzoic acid or its pharmaceutically acceptable salts, solvate or hydrate in preparing a drug for treating Duchene muscular dystrophy associated with nonsense mutation in position 1417, 3625 or 492 of dystrophin; and cystic fibrosis associated with nonsense mutation in position 414, 493, 1316, 553, 542, 1162, 122, 1455, 822, 60, 764, 1291, 849, 434, 88, 1158 or 6542 CTFR. What is also presented is the use of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazole-3-yl]benzoic acid or its pharmaceutically acceptable salts, solvate or hydrate in preparing a drug for producing a functional readthrough protein in a subject having Duchene muscular dystrophy and cystic fibrosis.

EFFECT: use of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazole-3-yl]benzoic acid provides suppression of premature termination of translation in a subject by mediating nonsense codon reading and producing the functional protein in the amount sufficient for treating the disease.

3 cl, 3 dwg, 17 tbl, 16 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, in particular to rehabilitating medicine, balneology, physiotherapy and pediatrics. Method of rehabilitation of sickly children with chronic foci of nasopharynx infections includes tempering with cooling agent in form of cryopacket with volume 500.0 ml from frozen water-cooling mixture, placed in elastic hermetic envelope, with temperature -23…-21°C, cryomassage of sole regions of child's feet being performed by circular stroking in clockwise direction with duration 7-20 seconds depending on child's age, procedure is carried out daily in the first half of the day, course includes 10 procedures, with continuation of treatment course to 7 months in out-patient way; intake of Se-containing mineral water inside is administered additionally in dose 100-150 ml 3 times per day, 40 minutes before meal, therapeutic exercise - daily, for 20-30 minutes, in the first half of the day; manual massage of collar area, every second day, 8-10 procedures per course, in the second half of the day - group halotherapy, with duration of procedure 25 minutes, daily in the second half of the day, 10-12 procedures per course, treatment duration constitutes 21-24 days.

EFFECT: invention ensures increase of immunologic resistance of organism, produces local anti-inflammatory, secretolytic effect and increases degree of stability and resistance of organism of children of primary school age to different cold-viral infections.

4 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to pulmonology, and may be used in treating the patients with cold bronchospasm and mucosal oedema in the patients with cold bronchial asthma. That is ensured by 2-3 inhalations of berodual and simbicort before walking in the open air at temperature (-20°C)-(-45°C).

EFFECT: method provides arrest of cold bronchospasm ensured by the prescribed dose schedule of the antasthmatics ensuring passability of both bronchial tubes, and the whole airway completely.

1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, particularly an antitussive and expectorant drug. The antitussive and expectorant composition containing the extract Coptidis rhizoma as an active ingredients wherein the extract represents a crude extract which is prepared by the use of one or more solvents specified in a group consisting of water and linear or branched alcohol having 1 to 4 carbon atoms as an extractant, or a solvent-soluble extract which is produced by adding an aqueous solution of linear or branched alcohol having 1 to 6 carbon atoms to the crude extract. The composition for treating a respiratory disease containing the antitussive and expectorant composition. A healthy functional foodstuff for relieving the respiratory disease containing the composition containing the extract Coptidis rhizoma as an active ingredient.

EFFECT: compositions and functional foodstuff are effective as the antitussive and expectorant composition.

8 cl, 5 dwg, 20 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: group of inventions relates to medical technology, in particular to method and device for control of state of patient's autonomous nervous system under anesthesia. Method is realised by device which includes measuring equipment for registration of signal of skin conductivity and control unit. In accordance with the method during interval of measurements signal of skin conductivity is registered, points of local minimums are identified, integration intervals are selected, function of linear inclination, as well as integral are calculated from difference of values of skin conductivity signal and linear inclination function in case, when signal of skin conductivity is higher than values of function of linear inclination, first index of state of patient's autonomous nervous system under anesthesia is calculated. Also, selected is subset of measurement interval values with beginning in the first point of minimum, value of skin conductivity is selected in said point as constant value, integral is calculated from difference of values of skin conductivity signal and said constant value in case, when signal of skin conductivity is higher than said constant value, second index of state of patient's autonomous nervous system under anesthesia is calculated. The larger of the first and the second indices is given as outlet signal, reflecting state of patient's autonomous nervous system under anesthesia.

EFFECT: application of group of inventions will make it possible to improve interpretability of measurement results, as well as will increase convenience and easiness of control of state of patient's autonomous nervous system under anesthesia.

11 cl, 6 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medical equipment, namely to methods and apparatuses for neurostimulation therapy. A neuromimetic apparatus comprises first and second inputs receiving neural signals with the first input receiving signals afferent to a suspected area and the second input - different from the suspected area. The input emitting neural compatible signals efferent to the suspected area. A signal processing unit comprises a forward channel arranged between the first input and output, and a modulation channel receiving signals from the second input and feeding a signal into the forward channel. The forward channel comprises a first sensor, a processor trained to imitate the suspected area functions which is a second neural area, a signal generator feeding signals to the efferent third area suggested to be healthy. A method for substitution of the suspected neural tissue functioning implies the stages of implantation of the neuromimetic apparatus, emission of at least one stimulus based on the processing function, signal control from the first and second inputs, signal sample comparison from the first and second inputs and emission sample adaptation on the basis of the comparison results.

EFFECT: use of the invention enables higher adaptability and flexibility for diagnosing and treating neuromotor outcomes, such as Parkinson's disease.

12 cl, 9 dwg

FIELD: medicine.

SUBSTANCE: invention relates to medical equipment. An apparatus comprises: two data retrieval electrodes placed on a tenth cranial nerve or cerebral portions, two stimulating electrodes placed on the tenth cranial nerve, a stimulation unit, a control unit. The stimulation unit comprises two series switchboards, an operating amplifier, a sigma particle, an analogue-to-digital converter, a microprocessor, a transmitter-receiver. A digital-to-analogue converter, a generator, a switchboard are series connected on a second output of the microprocessor. A magnetoelectric generator is connected to the microprocessor. A power element supplies the unit. The control unit consists of series transmitter-receiver, microcontroller. A real-time clock, a flash memory, USB microcircuit are parallel connected to the microcontroller. The power element supplies the unit. The control unit comprises a permanent magnet separated from the electric circuit by a screening wall in order to eliminate magnetism on the electric circuit.

EFFECT: invention provides higher clinical effectiveness ensured by adaptation of the apparatus to an epileptic seizure.

1 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely physiotherapy. A method involves electrostimulation at frequency 100 Hz with using an external apparatus of anal electrostimulation. The relation of stimulation and rest periods is specified taking into account functionality of the patient's neosphincter muscles by formula T = t x E/A wherein t is a time of volitional constriction of the anal sphincter, E is bioelectric activity of volitional constriction, A is bioelectric activity of test electrostimulation, T is a time of the electrostimulation period with a pause of the stimulation periods making 1.5 x T. The electrostimulation starts from the 13-14th postoperative day. Starting from the third postoperative month, the electrostimulation is applied at stimulating current frequency 80 Hz. Starting from the fourth postoperative month, the electrostimulation is applied at frequency 60 Hz. Starting from the fifth postoperative month - at frequency 40 Hz. Starting from the sixth postoperative month and to one year, the electrostimulation is applied at stimulating current frequency 20 Hz. A 1-week pause is made every 3 weeks of the electrostimulation course.

EFFECT: method provides the functional alteration of the created neosphincter with formation of tonic activity and neuroreflex activity, approaching the intestinal continence mechanism to the anal sphincter conditions.

2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medical equipment, namely matrixes for sensors and implanted devices. A method for making a neurostimulation chain involves creation of at least two stimulation assemblies each of which contains a polymer film comprising one or more conducting wires, and an open portion of the electrode for each conducting wire which has no polymer film, for baring of an electrode contact underlying on the end of the conducting wire. The stimulation assemblies are applied for placing of the polymer films contacting to each other and melt the polymer films together by thermal processing for making an integral neurostimulation chain having a number of conducting wires and properly bared electrode contacts.

EFFECT: using the invention allows reducing labour input in making implants.

10 cl, 9 dwg

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to ophthalmology, physiotherapy. Method is realised by carrying out electroneurostimulation of nervous-muscular apparatus of ciliary body. Electric stimulation is carried out by transcutaneous impact in paraorbital area. Impact is realised with frequency 65-85 Hz. In order to activate ciliary body muscles impact is performed with pulses with frequency 77 Hz and duration of bundles 2.5-3.5 ms. In order to reduce adaptation to stimulation impact is performed by change of amplitude of pulses in series at frequency 77 Hz.

EFFECT: method ensures improvement of intraocular fluid outflow, increase of accommodation reserve due to stimulation of muscular part of ciliary body.

3 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to physiotherapy. Method includes electric stimulation of muscles. Point electrodes are applied on person's body in regions of intersection of tendon portions of muscles responsible for posture formation: on anterior-lateral surfaces of hips above upper poles of kneecaps, behind greater trochanters of hips, in region of anterior upper spines of iliac bones and more medial than inferior angles of scapula. Alternating sinusoidal modulated current is supplied to electrodes until contraction of extensor muscles of knee and hip joints, prelum abdominale, extensors of trunk and inferior fixators of scapula is obtained. At obtained current intensity operation mode "sending pause", with length of sending 10 s, pause - 50 s, is set. While procedure is carried out, patient watches ammeter. Simultaneously with supply of electric current in "sending" period patient strains stimulated muscle: presses rest site, tightens the stomach, extends shoulder girdle and lowers shoulder blades. In "pause" period patient relaxes muscles. Duration of procedure is 12 minutes. Course includes 10 procedures.

EFFECT: method increases efficiency of electric stimulation of posture-forming muscles due to impact of electric signal both on synergist muscles and antagonist muscles, increases time of retention of obtain results.

2 ex, 1 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to - physiotherapy, balneology. A method involves basic drug-induced therapy, transcranial electrical stimulation and balneotherapy. The transcranial electrical stimulation is performed within the period from 11.00 to 15.00. The exposure is enabled by a frontooccipital technique with using pulse bipolar current with gradually increased current intensity from 0.8 to 1.2 mA to make evident painless vibration observed under electrode. Duration of a procedure is 30-40 minutes. The procedures are daily; the therapeutic course is 10-12 procedures. Within the period from 14.00 to 18.00, balneotherapy is prescribed with iodine-bromine baths at the concentration of sodium chloride 10 g/l, potassium bromide 25 g/l, potassium iodide 25 g/l. The procedures are daily; the therapeutic course is 9-10 procedures.

EFFECT: method provides higher therapeutic effectiveness ensured by improved psychological status, central and intracardial hemodynamic parameters, values of lipid exchange and antioxidant protection, intensified hypotension effect and improved microcirculation in reducing drug-induced load on patient's body.

2 ex, 3 tbl

FIELD: medicine.

SUBSTANCE: invention is referred to the field of medicine, namely - neurology and physiotherapy. The system includes an electrical stimulation lead suited for implantation into the epidural space overlying the medulla and their positioning on the skin for stimulation sessions. Two electrodes shall be introduced into the epidural space simultaneously. The electrodes shall be placed two-three vertebral sections more cephalically and caudally of the medullary damaging area. Immediately before the electric stimulation sessions electrodes shall be positioned on the skin, on the back surface of distal upper or lower limb surface. Only the electrodes in the epidural space or one electrode located cefalically in the epidural space and the electrodes positioned on paired limb segments shall be used for electric stimulation sessions in an alternate manner.

EFFECT: method prevents from complications of inflammatory and neurotic nature in the course of medullary electrostimulation, enhances exercise tolerance.

3 cl, 1 ex, 2 dwg

FIELD: medicine.

SUBSTANCE: inventions referred to medicine, colorectal surgery and can be used for perianal and sacrococcygeal area wound healing stimulation during the post surgical period in patients operated for anal fistula of various localizations, as well as for pilonidal cyst chronic inflammation treatment. For this purpose thermal treatment of recess and sinus tract cavity in the wound is performed. In this case a needle electrode is inserted into the wound surface bio-tissue down to 5-15 mm and is fed with impulse high-frequency current for 3-10 seconds, the current frequency being at the range of 2-6 MHz, relative impulse duration - 6-10, pulse repetition frequency - 1-10 kHz, voltage impulse amplitude - 160-200 V, average power - 3-5 W. The device consists of the high-frequency electric impulse generator, modulator providing for the required relative high-frequency current impulse duration, timer, foot lever, electronic unit for needle electrode metered shift device control, electro-mechanical needle electrode metered shift unit with a needle electrode.

EFFECT: reduction of the time required for perianal and sacrococcygeal area wound healing during the post surgical period in patients operated for anal fistula of various localizations; allows pilonidal cyst chronic inflammation treatment.

6 cl, 1 dwg, 1 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely - to gynecology, balneology, physiotherapy. Method includes taking baths and performing gynecological irrigations. Bath with mineral water from thermal radon springs, with natural water temperature about 38°C (radon water) is taken two days running, with the following one-day break. First procedure lasts 5 minutes, second - 8 minutes, third - 10 minutes, the following procedures being all 15 minutes long. The course includes 10 baths. In the first part of the day, two hours after breakfast, patient drinks 200 ml of radon water in swallows at a measured pace. After taking bath procedure is carried out according to the programme of resonance-acoustic fluctuations (PRAF), gynecological irrigations with radon water for 10-12-15 minutes and detensor-therapy are carried out. In the second part of the day, two hours after dinner, patient drinks 200 ml of radon water in swallows at a measured pace. On days when bath is not taken, intestinal lavage is performed in the first part of the day, and in the second part of the day hirudotherapy is performed. Hirudotherapy is performed on the 3 day - in zone of sacrum: the top of coccyx, area of sacrum projection. On the 6 day hirudotherapy is performed in the point on medium line, immediately above pubic bone and 1 and 4 centimetres outwards. On the 9 and 12 days hirudotherapy is performed intravaginally: in points of cervix, right or left fornicis.

EFFECT: method improves reproductive function due to positive impact on impaired metabolic, hormonal processes and psychoemotional state.

3 cl, 3 tbl

Up!